Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“ESMO Preview: New ADC Data for mTNBC!
Two major antibody-drug conjugate (ADC) trials are set to make waves in metastatic triple-negative breast cancer (mTNBC):
- TROPION-Breast02 (Dato-DXd) — first-line phase 3 trial testing datopotamab deruxtecan vs treatment of physician’s choice in patients ineligible for immunotherapy.
- ASCENT-03 (Sacituzumab Govitecan) — frontline study bringing sacituzumab into earlier therapy, also enrolling IO-ineligible patients.
Which ADC will come out on top?
Regardless of who “wins,” this is a win for patients. Only about 30 % of people with mTNBC ever make it to second-line treatment — so expanding effective first-line options is huge. More choices, more hope, and better access for those who need it most.
Stay tuned for the data drop at ESMO25 — this one’s going to be big.”
More posts featuring Matthew Kurian.